← Browse by Condition
Medical Condition
resected pancreatic adenocarcinoma
Total Trials
2
Recruiting Now
2
Trial Phases
Phase 3, Phase 2, Phase 3
ClinicalMetric tracks all active clinical trials for resected pancreatic adenocarcinoma sourced from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries — updated daily as new studies open and status changes.
- Recruiting trials currently enrolling participants, with eligibility criteria and age requirements
- Phase 1–4 studies from early safety trials to post-marketing surveillance
- NIH, pharmaceutical sponsor, and academic medical center studies worldwide
- AI-powered plain-language summary available for every trial listing
Trial Phases
Phase 2 1
Phase 3 2
Top Sponsors
1 trial
1 trial
Recruiting Clinical Trials
NCT07252232 Phase 3
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Enrollment
500 pts
Location
United States, Puert...
Sponsor
Revolution Medicines, Inc.
NCT07044453 Phase 2, Phase 3
Recruiting
Risk-adapted Adjuvant Chemotherapy Guided by the Tumour Stage for Operated Pancreatic Adenocarcinoma Following Neoadjuvant Chemotherapy With mFOLFIRINOX
Enrollment
390 pts
Location
France
Sponsor
University Hospital, Rouen
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology